Welcome to
Breckenridge Pharmaceutical, Inc.

 

Breckenridge Pharmaceutical, Inc. is a Towa Company. 

 TOWA PHARMACEUTICAL CO.,LTD.

We are an own label distributor that performs pharmaceutical marketing, sales and distribution in the U.S.  The company was founded in 1983 and markets a broad range of generic prescription products in several therapeutic categories and dosage forms, including tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders, transdermal patches, and injectable products.

The Breckenridge label is recognized nationwide by wholesalers, distributors, chains, managed care accounts, and retail pharmacies.

Breckenridge, headquartered in Berlin, Connecticut, markets products under more than 40 Abbreviated New Drug Applications (ANDAs) approved by the Food and Drug Administration (FDA).                                    

 

 

Latest News

Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC

Jun 22,2021

Breckenridge Pharmaceutical, Inc. announces today that it has signed a multi-product agreement with Aggrega Pharma, LLC. under which Aggrega will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.  The agreement currently covers eight products in a variety of dosage forms, including solid oral, nasal spray, ophthalmic, injectable and transdermal products. For these eight products, one ANDA has been approved, four ANDAs have been submitted to the U.S. Food and Drug Administration and three ANDAs are at advanced stages of development.  Breckenridge previously launched Succinylcholine Chloride Injection, USP, 20mg/mL under this agreement, which is now available from Breckenridge as a carton of 25 vials.   According to industry sales data, these eight products and their generics had annual sales of $500 million during the twelve months ending April 2021.

 

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

www.bpirx.com

 

 

About Aggrega Pharma, LLC:

Aggrega Pharma, LLC. is a first-class pharmaceutical company developing, manufacturing and marketing generic medications (injectable, ophthalmic, oral and topical finished dosage forms). The shareholders are 4 European companies:  Bluepharma, Rafarm, Substipharm and Welding. Aggrega Pharma is committed to building a pipeline of complex and selected generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members. Our portfolio includes products that are commercialized as well as products to be launched soon.

www.aggregapharma.com

Read More >>

Carfilzomib Approval Generic Kyprolis

Jun 15,2021

Breckenridge Announces Approval of its ANDA for Carfilzomib Intravenous Powder (generic for Kyprolis®)

 

 

Berlin, Connecticut, June 15, 2021

 

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Carfilzomib Intravenous Powder (generic for Kyprolis®). This product was developed in collaboration with Natco Pharma Limited.  Breckenridge received final approval for the 10mg and 60mg strengths and tentative approval for the 30mg strength.   Onyx Therapeutics, Inc., Breckenridge and Natco have reached a Settlement Agreement and the District Court case against Breckenridge and Natco has been dismissed. By virtue of the settlement, Breckenridge has been granted a license permitting the launch of its generic carfilzomib product on a date that is held as confidential in 2027 or sooner depending on certain occurrences. The parties cannot make further comment as to the terms of the Settlement Agreement. According to industry sales data, Kyprolis generated annual sales of $711 million during the twelve months ending April 2021. 

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

www.bpirx.com

 

About Natco:

Natco Pharma Limited is a global generic pharmaceutical research, development, manufacturing and marketing company. The company was established in 1981 in India. Natco supplies pharmaceutical products to over 50 countries across the globe, including the United States. Natco focuses on the development and manufacturing of oncology and other specialty pharmaceuticals.

www.natcopharma.co.in

Read More >>

Everolimus / Zortress Approval 06-01-2021

Jun 01,2021

Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (generic for Zortress®)

 

 

Berlin, Connecticut, June 1, 2021

 

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress®). This product was developed in collaboration with Natco Pharma Limited. According to industry sales data, Zortress and its therapeutic equivalents generated annual sales of $162 million during the twelve months ending March 2021.  Breckenridge plans to launch Everolimus Tablets in 0.25mg, 0.5mg and 0.75mg strengths during the third quarter of 2021 in a blister card packaging configuration.

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

www.bpirx.com

 

About Natco:

Natco Pharma Limited is a global generic pharmaceutical research, development, manufacturing and marketing company. The company was established in 1981 in India. Natco supplies pharmaceutical products to over 50 countries across the globe, including the United States. Natco focuses on the development and manufacturing of oncology and other specialty pharmaceuticals.

www.natcopharma.co.in

 

For further information, please contact:

Breckenridge Pharmaceutical, Inc.

Robert Gasparino, Associate Vice President – Business Development

Tel: 860-828-8140

E-mail: rgasparino@bpirx.com

 

*All brand names and trademarks are the property of their respective owners.

Read More >>

Product Search

All brand names are registered trademarks of their respective owner(s).